Foresite Capital Management IV’s Aerie Pharmaceuticals AERI Stock Holding History

Foresite Capital Management IV’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-227,717	Closed	-$3.07M	–	17
2020 Q1	$3.07M	Sell	227,717 -1,273,683	-85%	-$24.2M	3.79%	7
2019 Q4	$36.3M	Buy	1,501,400 +100,500	+7%	+$2.08M	15.66%	1
2019 Q3	$26.9M	Buy	1,400,900 +800,900	+133%	+$18.3M	8.7%	2
2019 Q2	$17.7M	Buy	600,000 +388,177	+183%	+$15M	5.01%	10
2019 Q1	$10.1M	Sell	211,823 -50,000	-19%	-$2.2M	3.62%	12
2018 Q4	$9.45M	Buy	+261,823	New	+$12.3M	4.34%	11

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Foresite Capital Management IV's AERI Position: Q2 2020 in Review

Foresite Capital Management IV sold out of Aerie Pharmaceuticals (AERI) in Q2 2020, closing a stake of 227,717 shares — an estimated $3.07M sold.

Foresite Capital Management IV first reported a position in AERI in Q4 2018 and held it in 6 quarters. The position peaked at $36.3M in Q4 2019. 155 funds tracked by Wall St. Rank hold AERI as of Q2 2020.

Foresite Capital Management IV reported no remaining Aerie Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Foresite Capital Management IV sold 227,717 Aerie Pharmaceuticals shares in Q2 2020, an estimated $3.07M.
Foresite Capital Management IV first reported a position in Aerie Pharmaceuticals in Q4 2018 and held it in 6 quarters.
Foresite Capital Management IV's Aerie Pharmaceuticals position peaked at $36.3M in Q4 2019.
155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2020.

Based on Foresite Capital Management IV's 13F filing for Q2 2020, filed 13 Aug 2020.